NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, INTO OR WITHIN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND,
SOUTH AFRICA AND SOUTH KOREA, OR ANY JURISDICTION IN WHICH THE RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Reference is made to the stock exchange notice on 16 July 2026 regarding the
optional cash offer from Aker Capital AS ("Aker Capital"), a wholly-owned
subsidiary of Aker ASA ("Aker"), to acquire all outstanding shares in Aker
BioMarine ASA ("Aker BioMarine") for NOK 105 per share (the "Cash Offer").

Upon expiry of the acceptance period in the Cash Offer on 30 July 2026, Aker
Capital has received acceptance of the Cash Offer for a total of 10,707,629
shares in Aker BioMarine.

Completion of the Cash Offer is conditional upon approval of the merger plan for
the merger between Aker BioMarine and Aker Capital NewCo AS announced on 16 July
2026 by an extraordinary general meeting in Aker BioMarine scheduled for 17
August 2026 (the "Aker BioMarine EGM"). Shareholders that have accepted the Cash
Offer may attend and vote their shares at the Aker BioMarine EGM.

Settlement of the Cash Offer will take place no later than three trading days
after approval of the merger plan by the Aker BioMarine EGM. Prior to completion
of the Cash Offer, Aker Capital will execute a forward contract with respect to
the shares tendered in the Cash Offer, whereby a financial institution on
completion of the Cash Offer will acquire the tendered shares with an obligation
for Aker Capital to physically settle the forward contract in connection with
completion of the Merger.

The complete terms and conditions of the Cash Offer are set out in the stock
exchange notice published on 16 July 2026.

-ENDS-

Investor contact:
Christopher Vinter, SVP Finance
+47 91 16 08 20
christopher.vinter@akerbiomarine.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 of the Norwegian Securities Trading Act. The information was
submitted for publication, through the agency of the contact persons set out
above, at 2026-07-31 06:55 CEST.

IMPORTANT INFORMATION

The terms and conditions of the Cash Offer will be governed by Norwegian law and
carried out in conformity with the requirements of Norwegian law. The Cash Offer
and the distribution of this announcement and other information in connection
with the Cash Offer may be restricted by law in certain jurisdictions,
including, without limitation Australia, Canada, Japan, New Zealand, South
Africa, South Korea and Hong Kong, or any other jurisdiction in which it would
be unlawful. Neither Aker nor Aker Capital assumes any responsibility in the
event there is a violation by any person of such restrictions. Persons in the
United States should review "Notice to U.S. Holders" below. Persons into whose
possession this announcement or such other information should come are required
to inform themselves about and to observe any such restrictions. 

This announcement is for information purposes only and is not an offer or a
tender offer document and, as such, is not intended to constitute or form any
part of an offer or the solicitation of an offer to purchase, otherwise acquire,
subscribe for, sell or otherwise dispose of any securities, or the solicitation
of any vote or approval in any jurisdiction, pursuant to the Cash Offer or
otherwise. The Cash Offer will not be made directly or indirectly in any
jurisdiction where either an offer or participation therein is prohibited by
applicable law or where any tender offer document or registration or other
requirements would apply in addition to those undertaken in Norway.

Notice to U.S. Holders 

Holders of Shares in the United States ("U.S. Holders") are advised that Aker
BioMarine's shares are not listed on a U.S. securities exchange and that Aker
BioMarine is not subject to the periodic reporting requirements of the U.S.
Securities Exchange Act of 1934, as amended (the "U.S. Exchange Act"), and is
not required to, and does not, file any reports with the U.S. Securities and
Exchange Commission thereunder. 

The Cash Offer will be made for the issued and outstanding shares of Aker
BioMarine (other than shares owned by Aker Capital), a company incorporated
under Norwegian law, and is subject to Norwegian disclosure and procedural
requirements, which are different from those of the United States. The Cash
Offer is made to U.S. Holders as a "Tier I" tender offer as provided in Rule
14d-1(c) of Regulation 14D under the U.S. Exchange Act, to the extent applicable
and subject to any available exemptions, and otherwise in compliance with the
disclosure and procedural requirements of Norwegian law, including with respect
to the Cash Offer timetable, settlement procedures and timing of payments, which
may be different from requirements or customary practices in relation to tender
offers for U.S. domestic issuers that are subject to the more fulsome
requirements of Regulation 14D and 14E under the U.S. Exchange Act. 

The Cash Offer will be made to U.S. Holders on the same terms and conditions as
those made to all other holders of shares to whom the Cash Offer is made. Any
information document will be disseminated to U.S. Holders in English on a basis
comparable to the method that such documents are provided to Aker BioMarine's
other shareholders to whom the Cash Offer is made. The Cash Offer will be made
by Aker Capital and no one else. U.S. Holders are encouraged to consult with
their own advisors regarding the Cash Offer. 

To the extent permissible under applicable law or regulations, Aker Capital and
its affiliates or brokers (acting as agents for Aker Capital or its affiliates,
as applicable) may from time to time and during the pendency of the Cash Offer,
and other than pursuant to the Cash Offer, directly or indirectly, purchase or
arrange to purchase, shares in Aker BioMarine or any securities that are
convertible into, exchangeable for or exercisable for such Shares outside the
United States, so long as those acquisitions or arrangements comply with
applicable Norwegian law and practice and the provisions of such exemption.
These purchases may occur either in the open market at prevailing prices or in
private transactions at negotiated prices. 

To the extent information about such purchases or arrangements to purchase is
made public in Norway, such information will be disclosed by means of an English
language press release via an electronically operated information distribution
system in the United States or other means reasonably calculated to inform U.S.
Holders of such information. In addition, the financial advisor to Aker and Aker
Capital may also engage in ordinary course trading activities in securities of
Aker BioMarine, which may include purchases or arrangements to purchase such
securities as long as such purchases or arrangements are in compliance with
applicable law. To the extent required in Norway, any information about such
purchases will be made public in Norway in the manner required by Norwegian law.


Neither the U.S. Securities and Exchange Commission nor any U.S. state
securities commission has approved or disapproved the Cash Offer, passed upon
the merits or fairness of the Cash Offer, or passed any comment upon the
adequacy, accuracy or completeness of the disclosure in this announcement. Any
representation to the contrary is a criminal offense in the United States. 

It may be difficult for Aker BioMarine's shareholders to enforce their rights
and any claims they may have arising under the U.S. federal securities laws in
connection with the Cash Offer, since Aker BioMarine, Aker and Aker Capital are
located in non-U.S. jurisdictions, and some or all of their respective officers
and directors may be residents of non-U.S. jurisdictions. The shareholders of
Aker BioMarine may not be able to sue Aker, Aker Capital or Aker BioMarine or
their respective officers or directors in a non-U.S. court for violations of the
U.S. federal securities laws. It may be difficult to compel Aker, Aker Capital
and Aker BioMarine and their respective affiliates to subject themselves to a
U.S. court's judgment.
for violations of the\
U.S. federal securities laws. It may be difficult to compel Aker\, Aker Capital\
and Aker BioMarine and their respective affiliates to subject themselves to a\
U.S. court's judgment.\